8/16/2022 7:37:13 AM
Qualigen Therapeutics Q2 Net Loss $4.1 Mln Or $0.11/Shr Vs Loss Of $5.4 Mln Or $0.19/Shr Last Year
6/7/2022 9:15:03 AM
Qualigen Announces IND-Enabling Studies To Advance Lead Program QN-302 Toward Clinical Trials
5/13/2022 6:25:26 AM
Qualigen Therapeutics Q1 Net Loss $4.3 Mln Or $0.12/Shr Vs Loss Of $5.2 Mln Or $0.19/Shr Last Year
5/3/2022 9:34:36 AM
Qualigen Therapeutics To Acquire Majority Stake In NanoSynex
1/26/2021 9:20:30 AM
Qualigen Completes Milestone Related To License And Tech Transfer Of FastPack Diagnostics Products In China